Placebo News and Research

RSS

FDA accepts Eisai's sNDA for perampanel drug for treatment of PGTC seizures

Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) accepted for review the company's Supplemental New Drug Application (sNDA) for its in-house-discovered AMPA receptor antagonist perampanel for the treatment of primary generalized tonic-clonic (PGTC) seizures.

20 Oct 2014

Regeneron, Sanofi announce initiation of dupilumab Phase 3 study in adults with atopic dermatitis

Regeneron Pharmaceuticals, Inc. and Sanofi today announced that the first patients have been dosed in a Phase 3 clinical study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, in adults with moderate-to-severe atopic dermatitis (AD) that is not adequately controlled with topical AD medications.

20 Oct 2014

Researchers receive NIH grant to study mechanisms of auditory hypersensitivity in fragile X syndrome

Fragile X syndrome (FXS) is a genetic disorder in humans that causes social impairments and repetitive behaviors, and other behaviors on the autistic spectrum, as well as cognitive deficits.

17 Oct 2014

Highland completes US$25 million offering of Class A Common Shares

Highland Therapeutics Inc., a pharmaceutical company, today announced it has completed a US$25 million offering of Class A Common Shares. The financing was led by a private equity partner that is committed to Highland's long-term success.

16 Oct 2014

Boehringer Ingelheim's OFEV (nintedanib) capsules receive FDA approval for IPF treatment

Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration approved OFEV (nintedanib) capsules for oral use for the treatment of idiopathic pulmonary fibrosis (IPF).

15 Oct 2014

Broccoli sprout compound may help ease classic behavioral symptoms in people with autism

Results of a small clinical trial suggest that a chemical derived from broccoli sprouts — and best known for claims that it can help prevent certain cancers — may ease classic behavioral symptoms in those with autism spectrum disorders (ASDs).

15 Oct 2014

High doses of fish oil supplements do not reduce atrial fibrillation

High doses of fish oil supplements, rich in omega-3 fatty acids, do not reduce atrial fibrillation, a common type of irregular heartbeat in which the heart can beat as fast as 150 beats a minute. The results of the AFFORD trial led by the Montreal Heart Institute were published in the Journal of the American College of Cardiology on October 7th.

14 Oct 2014

Lund University researchers explore personalised treatment for type 2 diabetes

Researchers at Lund University in Sweden are testing a treatment for type 2 diabetes which targets the disease mechanism itself - and not just the symptoms. For the first time, knowledge about the individual patient's genetic risk profile is being used. The treatment completely restores the capacity to secrete insulin, which is impaired by the risk gene.

14 Oct 2014

I.V. lidocaine can protect mastectomy patients against chronic pain

More than two-thirds of women who have had mastectomies struggle with persistent pain, but it doesn't have to be that way.

14 Oct 2014

Study shows diphenhydramine suppresses cough reflex sensitivity with Dr. Cocoa formulation

Cough is among the most common complaints for which patients seek medical attention. Leading cough researcher Peter V. Dicpinigaitis, M.D., Professor of Clinical Medicine at New York's Albert Einstein College of Medicine, recently conducted a new cough challenge study among adults, whose results were first presented at the European Respiratory Society International Congress in September 2014.

13 Oct 2014

Intensive parenting and education provided in homes reduces drug use in pregnant teens

Intensive parenting and health education provided in homes of pregnant American Indian teens reduced the mothers' illegal drug use, depression and behavior problems, and set their young children on track to meet behavioral and emotional milestones they may have otherwise missed.

13 Oct 2014

Isis Pharmaceuticals secures $18 million from GSK to advance ISIS-TTR Rx Phase 2/3 study

Isis Pharmaceuticals, Inc. announced today that it has earned an $18 million milestone payment from GlaxoSmithKline related to the advancement of the Phase 2/3 study of ISIS-TTRRx in patients with familial amyloid polyneuropathy (FAP).

9 Oct 2014

Boehringer Ingelheim announces availability of Striverdi Respimat Inhalation Spray 5 mcg in the U.S.

Boehringer Ingelheim today announced that Striverdi Respimat (olodaterol) Inhalation Spray 5 mcg is now available by prescription in pharmacies across the United States.

8 Oct 2014

FDA designates NurOwn as Fast Track product for ALS treatment

BrainStorm Cell Therapeutics Inc., a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that the United States Food and Drug Administration (FDA) has designated NurOwn as a Fast Track product for the treatment of amyotrophic lateral sclerosis (ALS, or Lou Gehrig's Disease).

7 Oct 2014

Acacia Pharma reports positive results from APD421 Phase 3 studies for management of PONV

Acacia Pharma announces positive Phase 3 results with APD421 for the management of post-operative nausea & vomiting (PONV). The data generated demonstrated a statistically significant reduction in the incidence of PONV with APD421 compared to placebo in adult surgical patients at moderate to high risk of suffering PONV (PONV is defined as any episode of emesis or use of antiemetic rescue medication in the first 24 hours after surgery).

7 Oct 2014

Vitamin D supplement significantly reduces symptoms of winter-related atopic dermatitis

A study conducted in more than 100 Mongolian schoolchildren found that daily treatment with a vitamin D supplement significantly reduced the symptoms of winter-related atopic dermatitis, a type of eczema.

5 Oct 2014

Energy drinks increase frequency of insomnia, nervousness in athletes

A study analysing the positive and negative effects of energy drinks on athletes has seen that, although in principle their sports performance was seen to improve by between 3% and 7%, there was also an increase in the frequency of insomnia, nervousness and the level of stimulation in the hours following competition.

3 Oct 2014

Depression contributes to abnormal pain processes in IBS patients

High rates of anxiety and depression amongst patients with irritable bowel syndrome (IBS) have led many researchers to believe there could be a causal relationship between psychological factors and IBS symptoms. Now, scientists in Germany have found clear evidence that patients with IBS process pain signals from the gut abnormally, and that disturbed brain responses to pain are particularly pronounced in patients with more depression symptoms.

3 Oct 2014

Nutritional supplement boosts growth in short, lean children

A balanced nutritional supplement promotes height and weight gain in lean prepubertal children with idiopathic short stature, show the findings of a randomised trial.

2 Oct 2014

Placenta-derived cells are safe for MS patients

Patients with Multiple Sclerosis (MS) were able to safely tolerate treatment with cells cultured from human placental tissue, according to a study published today in the journal Multiple Sclerosis and Related Disorders.

1 Oct 2014

Placebo News and Research

FDA accepts Eisai's sNDA for perampanel drug for treatment of PGTC seizures

Regeneron, Sanofi announce initiation of dupilumab Phase 3 study in adults with atopic dermatitis

Researchers receive NIH grant to study mechanisms of auditory hypersensitivity in fragile X syndrome

Highland completes US$25 million offering of Class A Common Shares

Boehringer Ingelheim's OFEV (nintedanib) capsules receive FDA approval for IPF treatment

Broccoli sprout compound may help ease classic behavioral symptoms in people with autism

High doses of fish oil supplements do not reduce atrial fibrillation

Lund University researchers explore personalised treatment for type 2 diabetes

I.V. lidocaine can protect mastectomy patients against chronic pain

Study shows diphenhydramine suppresses cough reflex sensitivity with Dr. Cocoa formulation

Intensive parenting and education provided in homes reduces drug use in pregnant teens

Isis Pharmaceuticals secures $18 million from GSK to advance ISIS-TTR Rx Phase 2/3 study

Boehringer Ingelheim announces availability of Striverdi Respimat Inhalation Spray 5 mcg in the U.S.

FDA designates NurOwn as Fast Track product for ALS treatment

Acacia Pharma reports positive results from APD421 Phase 3 studies for management of PONV

Vitamin D supplement significantly reduces symptoms of winter-related atopic dermatitis

Energy drinks increase frequency of insomnia, nervousness in athletes

Depression contributes to abnormal pain processes in IBS patients

Nutritional supplement boosts growth in short, lean children

Placenta-derived cells are safe for MS patients

Exploring the G:Box and for high-quality imaging

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Latest News